Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HDC in deals with Abbott and Quest for prostate cancer test

This article was originally published in Clinica

Executive Summary

Health Discovery Corporation (HDC) has struck two deals to out-license its cancer detection technology to leading players in the diagnostics market. Quest Diagnostics has acquired rights from HDC to develop and commercialise a noninvasive urine-based test for the detection of clinically-significant prostate cancer. In return, Quest will make payments, royalties and additional undisclosed financial considerations to Savannah, Georgia-based HDC. In a separate deal, Abbott has gained co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for the commercialisation of HDC’s tissue-based and urine-based tests for prostate cancer. Exact financial details of both deals were not disclosed. According to the American Cancer Society, there were around 186,320 new cases of prostate cancer in the US in 2008 and approximately 28,660 men will die of the disease in 2009.

Topics

UsernamePublicRestriction

Register

MT041735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel